This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Landay, A. L. Articles by Kagan, J. Search for Related Content PubMed PubMed Citation Articles by Landay, A. L. Articles by Kagan, J.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, 07 1995, 462-468, Vol 2, No. 4
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Interlaboratory variability of CD8 subset measurements by flow cytometry and its applications to multicenter clinical trials. NAID/NICHD Women and Infants Transmission Study Group

AL Landay, D Brambilla, J Pitt, G Hillyer, D Golenbock, J Moye, S Landesman and J Kagan
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.

Recent studies have demonstrated the utility of measuring subsets of CD8+ T cells as prognostic markers in epidemiology cohort studies of human immunodeficiency virus (HIV)-infected patients. Most of these studies evaluating the value of CD8+ T-cell subsets have been performed at single centers, and few data are available on variability in the measurement of the CD8+ cell populations in multicenter trials. In the current study, we addressed this question by evaluating interlaboratory variability from the five laboratories enrolled in the Women and Infants Transmission Study sponsored by the National Institutes of Health. This study evaluated 35 HIV-positive and 28 HIV-negative proficiency testing samples sent to the laboratories for evaluation. The study focused on the robust coefficient of variation (RCV) for CD38 (11%), HLA-DR (21%), and CD57 (15%) expression on the CD8+ population. Data from the current study indicated that the variability in these measurements is greater than that for CD3+ CD4+ (RCV, 5%) and CD3+ CD8+ (RCV, 5%) cells. Knowledge of the variability of the CD8+ subset measurements should guide investigators in the design and analysis of clinical trials and epidemiology studies. Ability to obtain improved interlaboratory agreement on CD8+ subset measurements will facilitate further evaluation of these markers in HIV studies.

This article has been cited by other articles:

• Hoover, D. R., Donnay, A., Mitchell, C. S., Ziem, G., Rose, N. R., Sabath, D. E., Yurkow, E. J., Nakamura, R., Vogt, R. F., Waxdal, M., Margolick, J. B. (2003). Reproducibility of Immunological Tests Used To Assess Multiple Chemical Sensitivity Syndrome. CVI 10: 1029-1036 [Abstract] [Full Text]  
• Rich, K. C., Fowler, M. G., Mofenson, L. M., Abboud, R., Pitt, J., Diaz, C., Hanson, I. C., Cooper, E., Mendez, H., for the Women and Infants Transmission Study Group, (2000). Maternal and Infant Factors Predicting Disease Progression in Human Immunodeficiency Virus Type 1-Infected Infants. Pediatrics 105: e8-e8 [Abstract] [Full Text]